Answer to Question 1
Correct Answer: 1,2,3
Rationale 1: Nausea and vomiting are an adverse effect of a direct cholinergic agonist such as bethanechol.
Rationale 2: Blurred vision is an adverse effect of a direct cholinergic agonist such as bethanechol.
Rationale 3: Orthostatic hypotension is an adverse effect of a direct cholinergic agonist such as bethanechol.
Rationale 4: Increased peristalsis is an expected effect of a direct cholinergic agonist such as bethanechol.
Rationale 5: A slow respiratory rate is an expected effect of a direct cholinergic agonist such as bethanechol.
Global Rationale: Nausea and vomiting, blurred vision, and orthostatic hypotension are adverse effect of a direct cholinergic agonist such as bethanechol. Increased peristalsis and a slow respiratory rate are both expected effects of a direct cholinergic agonist such as bethanechol.
Answer to Question 2
Correct Answer: 1,2
Rationale 1: This medication increases the amount of acetylcholine in cholinergic synapses in the brain, which improves memory.
Rationale 2: This medication increases the amount of acetylcholine in cholinergic synapses in the brain, which improves cognitive functioning.
Rationale 3: Acetylcholinesteras e inhibitors do not slow the progression of Alzheimer disease.
Rationale 4: Acetylcholinesteras e inhibitors do not cure Alzheimer disease.
Rationale 5: Acetylcholinesteras e inhibitors do not cause a long-term improvement in the progression of Alzheimer disease. Improvement is limited and short-lived.
Global Rationale: This medication increases the amount of acetylcholine in cholinergic synapses in the brain, which improves memory and cognitive functioning. Acetylcholinesteras e inhibitors do not slow the progression of Alzheimer disease or cure it. Acetylcholinesteras e inhibitors do not cause a long-term improvement in the progression of Alzheimer disease. Improvement is limited and short-lived.